|

CGT4859 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Cogent Biosciences, Inc.1

Indications

  • FGFR3 Genetic Alterations1
  • FGFR2 Genetic Alterations1
  • FGFR3 Gene Short Variants1
  • FGFR3 Gene Amplification1
  • FGFR3 Gene Fusion/Rearrangement1

Scottsdale, Arizona1 trial

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Mayo Clinic Scottsdale

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.